Two Sigma Investments, LP Unity Biotechnology, Inc. Transaction History

Two Sigma Investments, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.56 - $1.29 $52,645 - $121,272	-94,010 Reduced 69.58%	41,091 $23,000
Q1 2022 May 16, 2022	SELL	$0.72 - $1.86 $275,549 - $711,835	-382,707 Reduced 73.91%	135,101 $151,000
Q4 2021 Feb 14, 2022	BUY	$1.3 - $3.17 $329,669 - $803,886	253,592 Added 95.98%	517,808 $756,000
Q3 2021 Nov 15, 2021	BUY	$2.91 - $4.5 $302,474 - $467,743	103,943 Added 64.85%	264,216 $793,000
Q2 2021 Aug 16, 2021	BUY	$4.15 - $6.3 $161,991 - $245,914	39,034 Added 32.2%	160,273 $744,000
Q1 2021 May 17, 2021	BUY	$5.51 - $9.42 $668,026 - $1.14 Million	121,239 New	121,239 $727,000
Q3 2020 Nov 16, 2020	SELL	$2.94 - $12.43 $33,621 - $142,149	-11,436 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$5.28 - $9.67 $60,382 - $110,586	11,436 New	11,436 $99,000
Q1 2020 May 15, 2020	SELL	$5.0 - $7.6 $173,830 - $264,221	-34,766 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$5.99 - $8.38 $208,248 - $291,339	34,766 New	34,766 $251,000

4.41M

Ticker UBX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 14,036,200
Market Cap $20.6M
Description
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular d...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.